NAPRF News Alert Naspers Limited N Sh (NAPRF) 140.7953 02/15/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Naspers Limited N Sh (NAPRF) 140.7953 $NAPRF

Naspers Limited: Online classifieds joint ventures transactions closed
Business Wire - Thu Jan 08, 6:01PM CST
Naspers Limited (JSE: NPN.SJ and LSE: NPSN), Schibsted Media Group (SCH:Oslo), Telenor Group (TEL:Oslo) and Singapore Press Holdings (SPH:SP) announced on 13 November 2014 an agreement to establish joint ventures for the development of their online classifieds platforms in four key markets - Brazil, Indonesia, Thailand and Bangladesh.
SP: 22.89 (-0.27)

Naspers Limited (JSE:NPN) Today Announced Its Results for the Six Months Ended 30 September 2014
Business Wire - Mon Nov 24, 11:06PM CST
Naspers today announced financial results for the six months ended 30 September 2014. Revenues measured on an economic interest basis, including the proportionate contribution from associates and joint ventures, expanded 30% year on year (YoY). With the group's ecommerce and internet businesses growing ahead of pay-television and print, 72% of group revenues are now earned offshore.

Joining Forces to Develop Classifieds
Business Wire - Thu Nov 13, 3:00PM CST
Naspers Limited (JSE:NPN.SJ and LSE:NPSN), Schibsted Media Group (OSE:SCH), Telenor Group (OSE:TEL) and Singapore Press Holdings (SGX:SPH) today announced an agreement to establish joint ventures for the development of their online classifieds platforms in four key markets - Brazil, Indonesia, Thailand and Bangladesh.
SPH: 45.22 (+0.20), TEL: 70.76 (+0.38)

Naspers: Results of Annual General Meeting
Business Wire - Fri Aug 29, 6:00AM CDT
Naspers Limited ("Naspers" (JSE:NPN) (LSE:NPSN), the 100th annual general meeting (AGM) of Naspers Limited was held this morning, under the chairmanship of Mr Ton Vosloo, in the Naspers Centre at 40 Heerengracht, Cape Town, South Africa.
NPN: 15.19 (+0.14)

Naspers Limited Today Announced Its Results for the Year Ended 31 March 2014
Business Wire - Mon Jun 23, 2:44AM CDT
Naspers (JSE: NPN) today announced financial results for the year ended 31 March 2014. Consolidated revenue grew a robust 26% to R62,7bn, driven by both internet and pay-television businesses. Growth was funded mainly by development spend, which accelerated 79% to R7,7bn. This step-up limited core headline earnings, considered by the board to be an indication of sustainable earnings performance, to R8,6bn, marginally higher than last year. Core headline earnings per share amounted to R21,81 and a dividend increase of 10% to R4,25 per share has been proposed.
NPN: 15.19 (+0.14)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading